In this week’s round-up, we cover the latest industry news from the US FDA and the halt of an Alzheimer’s drug following a toxic reaction.
In a direct comparison, ProMIS Neurosciences’ oligomer-selective antibody (PMN310) reveals a potential advantage over other antibody therapeutics.
Accelerator has announced the launch of Magnolia Neurosciences, a company developing a new class of neuroprotective therapies for patients.
Results from the Phase III TOLEDO study suggests that treatment of Parkinson’s with apomorphine increases periods of good motor control and reduces periods when Parkinson’s disease medications are ineffective.
An independent data monitoring committee has advised that lanabecestat is unlikely to meet primary endpoints, leading to the decision to discontinue trials.
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke.
This week, our industry report covers neuroblastoma, DUB inhibitors for neurodegenerative diseases and pediatric multiple sclerosis.
ALKS 5461 accepted for review following previous refusal-to-file for depression: industry news round-up
In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis.
In this week’s industry news round-up we set the focus on Alzheimer’s disease (AD), with another clinical trial termination announced and a new framework for defining AD.
In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more about our selection of the highlights this week.